BR112021024109A2 - Composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática - Google Patents

Composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática

Info

Publication number
BR112021024109A2
BR112021024109A2 BR112021024109A BR112021024109A BR112021024109A2 BR 112021024109 A2 BR112021024109 A2 BR 112021024109A2 BR 112021024109 A BR112021024109 A BR 112021024109A BR 112021024109 A BR112021024109 A BR 112021024109A BR 112021024109 A2 BR112021024109 A2 BR 112021024109A2
Authority
BR
Brazil
Prior art keywords
fibrate
treatment
pharmaceutical compositions
fxr agonist
liver disease
Prior art date
Application number
BR112021024109A
Other languages
English (en)
Inventor
Leigh Macconell
Richard Pencek
Original Assignee
Intercept Pharmaceuticals Inc
Leigh Macconell
Richard Pencek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc, Leigh Macconell, Richard Pencek filed Critical Intercept Pharmaceuticals Inc
Publication of BR112021024109A2 publication Critical patent/BR112021024109A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática. a presente invenção refere-se a uma composição farmacêutica que compreende uma combinação de um agonista de fxr e um fibrato. também é divulgado o uso da combinação para o tratamento, melhoria ou prevenção de uma doença ou condição mediada por fxr, como colangite biliar primária (pbc).
BR112021024109A 2019-05-30 2020-05-29 Composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática BR112021024109A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962854859P 2019-05-30 2019-05-30
PCT/US2020/035353 WO2020243590A1 (en) 2019-05-30 2020-05-29 Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease

Publications (1)

Publication Number Publication Date
BR112021024109A2 true BR112021024109A2 (pt) 2022-03-22

Family

ID=71787120

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024109A BR112021024109A2 (pt) 2019-05-30 2020-05-29 Composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática

Country Status (13)

Country Link
US (1) US20220226350A1 (pt)
EP (1) EP3976049A1 (pt)
JP (1) JP2022536060A (pt)
KR (1) KR20220016146A (pt)
CN (1) CN114144185A (pt)
AU (1) AU2020284135A1 (pt)
BR (1) BR112021024109A2 (pt)
CA (1) CA3142358A1 (pt)
EA (1) EA202193334A1 (pt)
IL (1) IL288302A (pt)
MX (1) MX2021014585A (pt)
SG (1) SG11202113155XA (pt)
WO (1) WO2020243590A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021010996A2 (pt) 2018-12-05 2021-08-31 Sage Therapeutics, Inc. Esteroides neuroativos e seus métodos de uso
WO2023147141A1 (en) * 2022-01-28 2023-08-03 Intercept Pharmaceuticals, Inc. Combination therapy
CN116554252A (zh) * 2023-04-07 2023-08-08 华南理工大学 一种高结晶度别胆酸及其在制备预防和治疗胆汁淤积性肝病药物中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US860303A (en) 1905-02-18 1907-07-16 Tea Tray Company Of Newark Horn-support.
US3262580A (en) 1964-06-23 1966-07-26 Mcdowell Wellman Eng Co Slewable gantry crane
FR1498459A (pt) 1965-07-30 1968-01-08
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4058552A (en) 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
US3716583A (en) 1969-04-16 1973-02-13 Sumitomo Chemical Co Phenoxy carboxylic acid derivative
AT296986B (de) 1969-08-13 1972-03-10 Merz & Co Verfahren zur Herstellung von neuen α-Halogenphenoxy-isobutyroyl-β-nicotinoyl-glykolen
DE2230383C3 (de) 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
JPS5118954B2 (pt) 1972-02-04 1976-06-14
US3948973A (en) 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
DE2308826C3 (de) 1973-02-22 1980-03-27 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren Phenoxyalkancarbonsäureester von Oxyalkyltheophyllinen, Verfahren zu ihrer Herstellung und Arzneimittel
FR2244511B1 (pt) 1973-07-05 1977-07-15 Roussel Uclaf
ES8101585A1 (es) 1980-02-15 1980-12-16 Especialidades Farmaco Terape Procedimiento de obtencion de un nuevo compuesto antiateros-clerotico
EP0607536B1 (en) 1992-12-08 2001-01-24 Ss Pharmaceutical Co., Ltd. Arylamide derivatives
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
CA2307820C (en) 1997-10-27 2007-04-24 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US20030109467A1 (en) 2001-11-15 2003-06-12 Isis Pharmaceuticals Inc. Antisense modulation of human FXR expression
AU2389100A (en) 1998-12-23 2000-07-12 Glaxo Group Limited Assays for ligands for nuclear receptors
AU2409600A (en) 1999-01-07 2000-07-24 Tularik Inc. Fxr receptor-mediated modulation of cholesterol metabolism
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
WO2002072598A1 (en) 2001-03-12 2002-09-19 Roberto Pellicciari Steroids as agonists for fxr
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
US7259186B2 (en) 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
PT2712617T (pt) 2004-03-12 2017-02-13 Intercept Pharmaceuticals Inc Tratamento de fibrose usando ligandos fxr
WO2006121861A2 (en) 2005-05-05 2006-11-16 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
BRPI0707794A2 (pt) 2006-02-14 2011-05-10 Intercept Pharmaceuticals Inc compostos derivados de Ácido biliar, formulaÇÕes e composiÇÕes farmacÊuticas, bem como uso de ditos compostos
EA015632B9 (ru) 2006-05-24 2012-08-30 Эли Лилли Энд Компани Агонисты fxr
MX2008014959A (es) 2006-05-24 2008-12-09 Lilly Co Eli Compuestos y metodos para modular fxr.
EP2040713B1 (en) 2006-06-27 2014-06-18 Intercept Pharmaceuticals Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
WO2008039829A2 (en) 2006-09-26 2008-04-03 Ironwood Pharmaceuticals, Inc. Diphenylheterocycle cholesterol absorption inhibitors
EP2121621B1 (en) 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
US20080300235A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
US20080299118A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
BR122016011808B1 (pt) 2012-06-19 2021-09-21 Intercept Pharmaceuticals, Inc Processos para preparar a forma 1 de ácido obeticólico e o ácido obeticólico cristalino
SG11201503247UA (en) 2012-10-26 2015-06-29 Intercept Pharmaceuticals Inc Process for preparing bile acid derivatives
DK3360881T3 (da) 2013-05-14 2021-03-15 Intercept Pharmaceuticals Inc 11-hydroxy-6-substituerede derivater af galdesyrer og aminosyrekonjagater deraf som farnesoid X receptormodulatorer
BR112017016766B1 (pt) * 2015-02-06 2023-11-07 Intercept Pharmaceuticals, Inc Composição compreendendo um agonista fxr e fibrato, bem como uso para tratar doença hepática colestática
US11034717B2 (en) 2015-10-07 2021-06-15 Intercept Pharmaceuticals, Inc. Farnesoid X receptor modulators

Also Published As

Publication number Publication date
CA3142358A1 (en) 2020-12-03
EP3976049A1 (en) 2022-04-06
JP2022536060A (ja) 2022-08-12
SG11202113155XA (en) 2021-12-30
IL288302A (en) 2022-01-01
AU2020284135A1 (en) 2022-01-06
KR20220016146A (ko) 2022-02-08
WO2020243590A1 (en) 2020-12-03
CN114144185A (zh) 2022-03-04
EA202193334A1 (ru) 2022-03-14
US20220226350A1 (en) 2022-07-21
MX2021014585A (es) 2022-01-11

Similar Documents

Publication Publication Date Title
BR112021024109A2 (pt) Composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática
BR112017016766A2 (pt) composições farmacêuticas para terapia de combinação
BR112017021688A2 (pt) composições compreendendo uma combinação de um anticorpo anti-pd-1 e outro anticorpo
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112022012594A2 (pt) Dosagem de gama-hidroxibutirato (ghb)
BR112018070852A2 (pt) composições de dissulfeto de selênio para uso no tratamento de disfunção das glândulas meibomianas
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BR112015024530A2 (pt) composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto
BR112012024349A2 (pt) métodos de tratamento de carcinoma hepatocelular
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112018006445A2 (pt) métodos para tratar distrofia muscular
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
BR112021021537A2 (pt) Composições e métodos que usam um ou mais aminoácidos indutores de autofagia para potencializar o efeito músculo-esquelético de um ou mais aminoácidos anabólicos
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112019006329A2 (pt) métodos de tratamento de câncer do trato biliar
BR112017008312A2 (pt) novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms)
BR112013010367A2 (pt) métodos de prevenir e/ou reduzir a deposição de amiloide e a doença de alzheimer, composição, uso de uma composição, agonista de tlr4 isento de endotoxina, e, uso de uma agonista de tlr4 isento de endotoxina
BR112023001143A2 (pt) Conjugado, composto, composição farmacêutica, métodos para tratar uma doença e reduzir o nível de uma proteína brm alvo em um indivíduo
BR112017016378A2 (pt) composições da pró-droga de fumarato de monometila
BR112022001395A2 (pt) Métodos para administrar anticorpos anti-siglec-8 e corticosteroides
BR112016026470A8 (pt) composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]